Last reviewed · How we verify

ropivacaine and midazolam intraarticular administration

Universidad Autonoma de Nuevo Leon · Phase 2 active Small molecule

ropivacaine and midazolam intraarticular administration is a Small molecule drug developed by Universidad Autonoma de Nuevo Leon. It is currently in Phase 2 development. Also known as: Ropiconest®, Ralecum®.

At a glance

Generic nameropivacaine and midazolam intraarticular administration
Also known asRopiconest®, Ralecum®
SponsorUniversidad Autonoma de Nuevo Leon
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ropivacaine and midazolam intraarticular administration

What is ropivacaine and midazolam intraarticular administration?

ropivacaine and midazolam intraarticular administration is a Small molecule drug developed by Universidad Autonoma de Nuevo Leon.

Who makes ropivacaine and midazolam intraarticular administration?

ropivacaine and midazolam intraarticular administration is developed by Universidad Autonoma de Nuevo Leon (see full Universidad Autonoma de Nuevo Leon pipeline at /company/universidad-autonoma-de-nuevo-leon).

Is ropivacaine and midazolam intraarticular administration also known as anything else?

ropivacaine and midazolam intraarticular administration is also known as Ropiconest®, Ralecum®.

What development phase is ropivacaine and midazolam intraarticular administration in?

ropivacaine and midazolam intraarticular administration is in Phase 2.

Related